Abstract 10678: Pharmacokinetic and Pharmacodynamic Effects of Prasugrel and Clopidogrel According to CYP2C19 Genotype in Very Elderly and Non-Elderly Patients With Coronary Artery Disease
Paul A. Gurbel(Sinai Hospital), David Erlinge(Lund University), Brian A. Moser(Eli Lilly (United States)), Dominick J. Angiolillo(University of Florida), Tomas Lindahl(Linköping University), Suman Duvvuru(Eli Lilly (United States)), Stefan James(Uppsala University), Patricia Brown(Eli Lilly (United States)), Scott S. Sundseth, Kenneth J. Winters(Eli Lilly (United States)), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Joseph R. Walker(Daiichi Sankyo (United States)), Jurriën M. ten Berg(St. Antonius Ziekenhuis), David S. Small(Eli Lilly (United States)), Peter J. Svensson(Skåne University Hospital)
Circulation
November 20, 2012
Cited by 0
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k
Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
|New England Journal of Medicine|2013|2.8k